Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adj...

Teva Pharmaceutical Industries Limited is regaining investor interest as restructuring efforts drive margin improvements and unlock pipeline potential. Turnaround: company is changing to a more profitable company. Duvakitug and the company's other pipelines have significant future potential.

For a lot of investors, earnings season is the highlight of every quarter. It's the roughly six-week period where most S&P 500 components report their operating results and give investors an inside look at how "healthy" corporate America really is.

Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website.

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment market. So, global sales of Austedo, widely used among neurologists for the treatment of tardive dyskinesia, reached $498 million in Q2 2025, an increase of 21.2% quarter-on-quarter. On September 20,...

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Richard Francis - President, CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division Get going with our next company presenter at the BofA H...